O
ARVN icon

OrbiMed’s Arvinas ARVN Stock Holding History

OrbiMed’s Portfolio ARVN Stock Details ARVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-29,400
Closed -$986K – 146
2020
Q2 		$986K Sell
29,400
-965,600
-97% -$41M 0.01% 134
2020
Q1 		$40.1M Sell
995,000
-903,800
-48% -$42.3M 0.67% 45
2019
Q4 		$78M Sell
1,898,800
-196,483
-9% -$5.75M 1.11% 33
2019
Q3 		$45.2M Sell
2,095,283
-583,527
-22% -$14.3M 0.86% 36
2019
Q2 		$58.9M Hold
2,678,810
– – 0.91% 36
2019
Q1 		$39.5M Hold
2,678,810
– – 0.61% 48
2018
Q4 		$34.4M Buy
2,678,810
+32,945
+1% +$523K 0.64% 51
2018
Q3 		$44.6M Buy
+2,645,865
New +$43.6M 0.54% 59

Other funds holding ARVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CPI
Canaan Partners IX Menlo Park, California $87.5M AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OrbiMed's ARVN Position: Q3 2020 in Review

OrbiMed sold out of Arvinas (ARVN) in Q3 2020, closing a stake of 29,400 shares — an estimated $986K sold.

OrbiMed first reported a position in ARVN in Q3 2018 and held it in 8 quarters. The position peaked at $78M in Q4 2019. 141 funds tracked by Wall St. Rank hold ARVN as of Q3 2020.

  • OrbiMed reported no remaining Arvinas position as of Q3 2020 after selling out during the quarter.
  • OrbiMed sold 29,400 Arvinas shares in Q3 2020, an estimated $986K.
  • OrbiMed first reported a position in Arvinas in Q3 2018 and held it in 8 quarters.
  • OrbiMed's Arvinas position peaked at $78M in Q4 2019.
  • 141 funds tracked by Wall St. Rank held Arvinas as of Q3 2020.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.